Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Nat Methods. 2012 Jul 1;9(8):805–807. doi: 10.1038/nmeth.2030

Figure 2. Modification of endogenous human genes by direct delivery of ZFN proteins.

Figure 2

(a) Frequency of endogenous CCR5 gene disruption in HEK293, THP1, HDF and CD4+ T cells subjected to three consecutive treatments with ZFN proteins using transient hypothermic conditions, as determined by the Surveyor nuclease assay. Black arrow indicates specific cleavage product. (b) DHFR production measured by fluorescein-methotrexate binding in CHO cells subjected to three consecutive treatments with ZFN proteins using standard or transient hypothermic conditions. Mock treated CHO cells exhibited approximately 1% reduction in functional DHFR (not shown). (c) Proliferation of HEK293, HDF and THP1 cells treated with ZFN proteins targeting the CCR5 gene and containing Sharkey mutations. (d) Proliferation of CHO cells treated with ZFN proteins targeting the DHFR gene and utilizing a variety of specialized cleavage domains. Values normalized to mock treated cells. Error bars indicate s.d. (n = 3).